Mechanisms of Disease: Cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy

Nature Clinical Practice Oncology

Volumn 3, Issue 10, 2006, Pages 564-574

  Drosten, Matthias ^a   Pützer, Brigitte M ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; AG 013736; AMG 706; ANTINEOPLASTIC AGENT; APTAMER; BEVACIZUMAB; CEP 701; CEP 751; CETUXIMAB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; IRINOTECAN; MONOCLONAL ANTIBODY; OXINDOLE DERIVATIVE; PD 173074; PEGAPTANIB; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE 1; PYRAZOLOPYRIMIDINE 2; PYRAZOLOPYRIMIDINE DERIVATIVE; RECEPTOR BLOCKING AGENT; RIBOZYME; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; RET PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; AUTOPHOSPHORYLATION; CARCINOGENESIS; CLINICAL TRIAL; DIMERIZATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; EXPERIMENTAL NEOPLASM; GENE FUNCTION; GENE STRUCTURE; GENE TARGETING; HUMAN; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; CELL TRANSFORMATION; DRUG EFFECT; DRUG THERAPY; GENETICS; MEDULLARY CARCINOMA; ONCOGENE; PATHOPHYSIOLOGY; PHYSIOLOGY; THYROID TUMOR;

CARCINOMA, MEDULLARY; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DRUG THERAPY; HUMANS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 33750596636     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0610     Document Type: Review

References (79)

1. Weinstein IB (2GO2) Cancer: Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64
2. Fischer OM et al. (2003) Beyond Herceptin and Gleevec. Curr Opin Chem Biol 7: 490-495
3. Ross JS et al. (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122: 598-609
4. Vitale G et al. (2001) Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 9l: 1797-1808
5. Quayle FJ and Moley JF (2005) Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes. J Surg Oncol 89: 122-129
6. Pützer BM and Drosten M (2004) The RET proto-oncogene: A potential target for molecular cancer therapy. Trends Mol Med 10: 351-357
7. Arighi E et al. (2005) RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16: 441-467
8. Airaksinen MF and Saarma M (2002) The GDNF family: Signaling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394
9. Coutpier M et al. (2002) Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: Importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 277: 1991-1999
10. Baloh RH et al. (2000) The GDNF family ligands and receptors-implications for neural development. Curr Opin Neurobiol 10: 103-110
11. Schuchardt A et al. (1994) Defects in the kidney and enteric nervous system in mice lacking the tyrosine kinase receptor Ret. Nature 367: 380-383
12. Sanchez M P et al. (1996) Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382: 70-73
13. Cacalano G et al. (1998) GFRα1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 21: 53-62
14. Jain S et al. (2 004) Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development 131: 5503-6513
15. Takahashi M (2001) The GDNF/RET signaling pathways and human diseases. Cytokine Growth Factor Rev 12: 361-373
16. Manie S et al. (2001) The RET receptor: Function in development and dysfunction in congenital malformation. Trends Genet 17: 580-689
17. Jijiwa M et al. (2004) A targeted mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 24: 8026-8036
18. Wong A et al. (2005) Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol Cell Biol 25: 9661-9673
19. Schuringa JJ et al. (2001) MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene 20: 5350-5358
20. Schuetz G et al. (2004) The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells. J Cell Biol 1167: 945-952
21. Basset V et al. (2000) Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J Biol Chem 275: 39 159-39 166
22. Hayashi H et al. (2000) Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19: 4469-4475
23. Coleman ML et al. (2004) RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5: 355-366
24. Vivanco I and Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 498-501
25. Degl'Innocenti D et al. (2004) Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching. Oncogene 23: 7297-7309
26. Hayashi Y et al. (2001) Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation. Biochem Biophys Res Commun 281: 682-689
27. Borrello MG et al. (1996) The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phosphlipase Cγ. Mol Cell Biol 16: 2151-2163
28. Gimm O (2001) Thyroid cancer. Cancer Lett 163: 143-156
29. Hundahl SA et al. (1998) A National Cancer Database report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83: 2638-2648
30. Leboulleux S et al. (2004) Medullary thyroid carcinoma. Clin Endocrinol 61: 299-310
31. Cohen MS and Moley JF (2003) Surgical treatment of medullary thyroid carcinoma. J Intern Med 253: 616-626
32. Brandi ML et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671
33. Mulligan LM et al. (1993) Germ-fine mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460
34. Hofstra RM et al. (1994) A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375-376
35. Eng C et al. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276: 1575-1579
36. Asai N et al. (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia type 2 mutations. Mol Cell Biol 15: 1613-1619
37. Santoro M et al. (1995) Activation of RET as a dominant-transforming gene by germline mutations of MEN2A and MEN2B. Science 267: 381-383
38. Bocciardi R et al. (1997) The multiple endocrine neoplasia type 2B mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 115: 2257-2265
39. Salvatore D et al. (2001) Increased in vivo phosphorylation of tyrosine 1062 is a potential pathogenic mechanism of multiple endocrine neoplasia type 2B. Cancer Res 61: 1426-1431
40. Carlomagno F et al. (1995) Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 207: 1022-1028
41. Drosten M et al. (2004) Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 96: 1231-1239
42. Wang DG et al. (1998) Bcl-2 and c-myc, but not bax and p53, are expressed during human medullary thyroid carcinoma tumorigenesis. Am J Pathol 152: 1407-1413
43. Reynolds L et al (2001) C-cell and thyroid epithelial tumors and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene 20: 3986-3994
44. C634Y inhibits both the wild-type and the constitutively activated RET. Biochem J 372: 897-903
45. Doggrell SA (2005) Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration. Exp Opin Pharmacother 6: 1421-1423
46. Cerchia L et al. (2005) Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PloS Biol 3: E123
47. Cosma MP et al. (1998) Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism. Mol Cell Biol 18: 3321-3329
48. Drosten M et al. (2002) A new therapeutic approach in medullary thyroid cancer treatment: Inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery 132: 991-997
49. Drosten M et al. (2003) Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 14: 971-982
50. Böckmann M et al. (2004) Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med 7: 179-188
51. Böckmann M et al. (2005) Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Hum Gene Ther 16: 1267-1275
52. Lanzi C et al. (2000) Inhibition of the transforming activity of the ret/ ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 85: 384-390
53. Cuccuru G et al. (2004) Cellular effects and antitumor activity of the RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96: 1006-1014
54. Bain J et al. (2003) The specificities of protein kinase inhibitors: An update. Biochem J 371: 199-204
55. Carlomagno F et al. (2002) The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62: 1077-1082
56. Carlomagno F et al. (2003) Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 88: 1897-1902
57. Melillo RM et al. (1999) Ret-mediated mitogenesis requires Src kinase activity. Cancer Res 59: 1120-1126
58. Carniti C et al. (2003) PP1 inhibitor induces degradation of RETMEN2A and RETMEN28 oncoproteins through proteosomal targeting. Cancer Res 63: 2234-2243
59. Warmuth M et al. (2003) Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101: 664-672
60. Heymach VJ (2005) ZD6474-clinical experience to date. Br J Cancer 92: S14-S20
61. Carlomagno F et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62: 7284-7290
62. Vidal M et al. (2005) ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65: 3538-3541
63. Carlomagno F et al. (2004) Disease associated mutations at valine 804 of the RET receptor tyrosine kinase confer resistance to selective tyrosine kinase inhibitors. Oncogene 23: 6056-6063
64. Carlomagno F and Santoro M (2005) Receptor tyrosine kinases; as targets for anticancer therapeutics. Curr Med Chem 12: 1773-1781
65. Strock CJ et al. (2003) CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63: 5559-5563
66. Strock CJ et al. (2006) Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 91: 79-84
67. Aggarwal S and Chu E (2005) Current therapies for advanced colorectal cancer. Oncology 19: 589-595
68. Cohen MS et al. (2002) Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132: 960-967
69. Skinner MA et al. (2003) RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of ST1571. Anticancer Res 23: 3601-3606
70. Ezzat S et al. (2005) Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11: 1336-1341
71. Konstantinopoulos PA and Papavassiliou AG (2005) 17-AAG: Mechanisms of antitumor activity. Expert Opin Investig Drugs 14: 1471-1474
72. Wilhem SM et al. (2004) BAY 43-9006 exhibits a broad spectrum antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109
73. Carlomagno et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98: 326-334
74. McKeage K and Perry CM (2002) Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62: 209-243
75. Yano L et al (2000) Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther 11: 995-1004
76. Parthasarathy R et al. (1999) Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 59: 3911-3914
77. Hennige AM et al. (2001) Inhibition of RET oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 142: 4441-4447
78. Deininger M et al. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653
79. Wells SA and Nevins JR (2004) Evolving strategies for targeted cancer therapy - past, present, and future. J Natl Cancer Inst 96: 980-981